Company: IMCR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001671927-25-000014
Chunk: 65

Company: Immunocore Holdings plc
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 65
---
05Exercise price$28.63 - $29.06$46.05 - $62.94$28.63 - $29.60$46.05 - $70.05Expected volatility52.92%  - 53.65%55.24% - 57.04%52.92% - 55.78%55.24% - 66.17%Expected life5.5 years5.5 years5.5 years5 years - 5.5 yearsRisk free rate3.94% - 4.12%4.34% - 4.56%3.94% - 4.41%3.93% - 4.56%Fair value$15.11 - $15.27$25.23 - $34.99$15.11 - $16.21$25.23 - $40.47Restricted share unit activityIn February 2025, the Company granted RSU awards that vest over a four-year service period with 25% on each anniversary of the grant date. An RSU award represents the right to receive one of the Company’s ADSs upon vesting of the RSU. The fair value of each RSU award is based on the closing price of the Company’s ADSs on Nasdaq on the date of grant. 

12

Table of Contents

The number and weighted average fair value of RSUs were as follows:Number of RSUsWeighted Average Grant Date Fair ValueUnvested and outstanding as of December 31, 2024— $— Awards granted489,50229.59 Awards vested — — Awards forfeited (9,509)29.60 Unvested and outstanding as of June 30, 2025479,993 $29.59 

As of June 30, 2025, total unrecognized compensation expense related to RSUs granted but not vested was $10.2 million, which the Company expects to recognize over a remaining weighted-average period of 2.2 years. 

7. Basic and diluted net loss per share

Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share amounts):Three Months Ended June 30,Six Months Ended June 30,2025202420252024Net loss$(10,300)$(11,616)$(5,277)$(36,052)Basic and diluted weighted-average number of shares outstanding50,